In 1993, 14,500 new cases of central nervous system tumors were diagnosed in the U.S. The most malignant of these, glioblastoma multiforme, remain a uniformly fatal disease with mean survival of less than one year from the time of diagnosis despite aggressive therapeutic interventions with surgery, chemotherapy, and radiotherapy. Patients die with diffuse invasion of the brain by tumor cells often without significant tumor bulk. The role of these invasive tumor cells in the demise of the patient is not clearly understood. Glial tumor cell locomotion is well documented in vitro and in vivo, but characterization of the exact nature of this locomotion remains limited. Preliminary studies completed in Dr. Silbergeld's (Pi's co-sponsor) laboratory indicate fundamental differences between human glial tumor cells which remain stationary, and those that are motile. Glioma invasion into normal brain represents the culmination of a series of events involving cellular locomotion, chemo- attractants, cell-cell interactions, adherence molecules (immunoglobulins, integrins, selectins), tumor cell proteinases, and proteinase inhibitors. The PI intends to further characterize the locomotion component of in vivo glial tumor cell invasion, and evaluate specific aspects of the cell biology in vitro that confer differences in locomotion upon subpopulations of these cells. Establishment of tumor cell lines from bulk tumor, and from histologically normal brain from outside bulk tumor utilizing genetically labeled tumor cells will enable focused comparison of these two cell lines with respect to motility, growth kinetics, and sensitivity to chemotherapeutic agents. An understanding of the biology of invasive malignant glioma cells is the first step toward the development of therapies specifically designed to target these important cells. The question addressed by this proposal are fundamental to this understanding, and should help provide avenues critical to the development of new treatment modalities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32CA067493-01
Application #
2111205
Study Section
Pathology A Study Section (PTHA)
Project Start
1995-08-23
Project End
Budget Start
1995-03-01
Budget End
1996-02-29
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Washington University
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Hippen, K L; O'Connor, R S; Lemire, A M et al. (2017) In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. Am J Transplant 17:3098-3113
Lu, Yunjie; Hippen, Keli L; Lemire, Amanda L et al. (2016) miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood 128:1424-35
Singh, K; Stempora, L; Harvey, R D et al. (2014) Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant 14:2691-703
Sawitzki, Birgit; Brunstein, Claudio; Meisel, Christian et al. (2014) Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant 20:173-82
Hawasli, Ammar H; Rubin, Joshua B; Tran, David D et al. (2013) Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 74:136-41
Singh, K; Kozyr, N; Stempora, L et al. (2012) Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 12:1441-57
Zanin-Zhorov, Alexandra; Lin, Jiqiang; Scher, Jose et al. (2012) Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function. Proc Natl Acad Sci U S A 109:1625-30
Hippen, Keli L; Bucher, Christoph; Schirm, Dawn K et al. (2012) Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 119:619-28
Plesa, Gabriela; Zheng, Lingjie; Medvec, Andrew et al. (2012) TCR affinity and specificity requirements for human regulatory T-cell function. Blood 119:3420-30
Ustun, Celalettin; Miller, Jeffrey S; Munn, David H et al. (2011) Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 118:5084-95

Showing the most recent 10 out of 21 publications